AbbVie unveils Venclexta data that scored lightning-fast leukemia combination nod Last month, partners AbbVie and Roche nabbed a speedy approval for Venclexta and Gazyva in chronic lymphocytic leukemia. And Tuesday, […]
Lilly’s scored its cluster headache nod for Emgality. Will it shake up the CGRP race? Eli Lilly’s Emgality didn’t just hit the next-gen migraine market in third place behind Amgen’s […]
Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more It’s that time of year again—the time when lead pharmacy benefits manager Express Scripts ignites pharma’s ire […]
With patisiran launch in its sights, Alnylam plots a major hiring spree Alnylam’s first drug approval could come any day now, and the company is bulking up to get ready—in […]
FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote Paratek Pharmaceuticals’ first drug, and the first in a new class of broad-spectrum antibiotics called aminomethylcyclines, has shown to […]